Abstract: Biguanides and thiazolidinediones can reduce the risk of liver cancer in diabetic patients and help improve the prognosis of patients with liver cancer and diabetes, while insulin and insulin similitude or sulfonylureas may increase the risk of liver cancer in diabetic patients and are associated with poor prognosis.Glucagonlike peptide-1(GLP-1)receptor agonists and sodium-glucose cotransporter protein-2(SGLT-2)inhibitors help improve hepatic steatosis and fibrosis and are expected to become therapeutic agents for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), thereby reducing the risk of liver cancer in diabetic patients and delay the progression of liver cancer.This review summarizes the relationship between commonly used clinical hypoglycemic drugs and the occurrence and development of liver cancer as well as the related mechanisms, aiming to provide reference for the selection of hypoglycemic drugs for patients with diabetes and liver cancer.